MedTrace Logo

Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis

NCT03208803 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2022-07-20

No results posted yet for this study

Summary

In patients with myelofibrosis, ruxolitinib is a current therapeutic option, which has demonstrated rapid and durable reduction in splenomegaly and improved disease-related symptoms. Anemia is another frequent issue in myelofibrosis. Consistent with its JAK2 signalling inhibition, ruxolitinib therapy has been shown to be detrimental on the hemoglobin level, increasing the depth of anemia or transfusion need.

Despite potential antagonistic mechanisms of action on Janus Kinase 2, some responses on anemia have been reported with the addition of Erythropoiesis-stimulating Agent to ruxolitinib in a small subset of patients in the COMFORT II study.

Ruxo-EPO is an observational study aimed to better assess the combination of Erythropoiesis-stimulating Agent and a Janus Kinase 2 inhibitor for therapeutic efficacy on anemia, Myelofibrosis evolution and for tolerance, in a larger cohort of patients treated for myelofibrosis in general practice.

Conditions

  • Myelofibrosis; Anemia

Sponsors & Collaborators

  • Centre Hospitalier Annecy Genevois

    lead OTHER

Principal Investigators

  • Sandra Malak, MD · Hôpital René Huguenin - Institut Curie - St Cloud - France

  • Lydia Roy, MD · Hôpital Henri Mondor - Créteil - France

  • Pascale Cony-Makhoul, MD · CH Annecy Genevois - Pringy - France

  • Mathieu Wemeau, MD · CH Arras

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2016-12-31
Completion
2016-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03208803 on ClinicalTrials.gov